Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Basit Öğe Kaydı
dc.contributor.authorKahraman, Seda
dc.contributor.authorErul, Enes
dc.contributor.authorGümüşay, Özge
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorAksoy, Sercan
dc.contributor.authorBaşaran, Gül
dc.contributor.authorSeyyar, Mustafa
dc.contributor.authorÖzkanlı, Gülhan
dc.date.accessioned2025-05-29T02:54:03Z
dc.date.available2025-05-29T02:54:03Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground: Real-world (RW) data provide valuable information about the effectiveness and safety of treatment modalities in the general population that is not limited by selection criteria in clinical studies. The aim of this study was to evaluate the effectiveness of palbociclib or ribociclib plus fulvestrant in hormone receptor-positive and human epidermal factor 2-negative metastatic breast cancer (HR+/HER2-MBC). Materials and methods: We conducted a multicenter, retrospective cohort study that included 522 patients with HR+/HER2-MBC treated with ribociclib or palbociclib in combination with fulvestrant. Results: Median real-world progression-free survival (mPFS) was 12.9 months (95% CI, 11.16-14.65) for the entire cohort, and no statistically significant difference was present between the palbociclib and ribociclib groups (P = .70). Real-world median overall survival (mOS) was estimated to be 43.3 months (95% CI, 20-66.6) for the palbociclib group and 48.5 months (95% CI, NA-NA) for the ribociclib group and similar between the 2 groups (P = .56). When evaluated for the entire group, there was a significant difference in mPFS between patients with primary and secondary endocrine resistance (8.6 and 13.5 months, P = .002), and this difference was more pronounced in the palbociclib arm (6.6 and 14.4 months, P = .006) than in the ribociclib arm (11.6 and 13.3 months, P = .064). Conclusion: Although the 3 CDK4/6 inhibitors did not seem to differ significantly from each other in terms of effectiveness in a real-world context, they may vary depending primarily on the specific characteristics of the patient population being treated. © 2025 Elsevier Inc.
dc.identifier.doi10.1016/j.clbc.2025.03.003
dc.identifier.issn1526-8209
dc.identifier.scopus2-s2.0-105001952865
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.clbc.2025.03.003
dc.identifier.urihttps://hdl.handle.net/20.500.12428/29908
dc.identifier.wosWOS:001513877300025
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier Inc.
dc.relation.ispartofClinical Breast Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20250529
dc.subjectCDK 4/6 inhibitors
dc.subjectFulvestrant
dc.subjectHR-positive
dc.subjectMetastatic breast cancer
dc.subjectReal-world data
dc.titleReal-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Gulhan Ozkanli_Makale.pdf
Boyut:
1.27 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu